Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy

Volumn 52, Issue 8, 2018, Pages 769-779

  Cho, Jonathan C ^a   Zmarlicka, Monika T ^b   Shaeer, Kristy M ^c   Pardo, Joe ^d  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

^b MARICOPA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

antibiotic resistance; antibiotics; bacterial infections; infectious disease; urinary tract infections

Indexed keywords

MEROPENEM; MEROPENEM PLUS VABORBACTAM; PENICILLIN BINDING PROTEIN; PIPERACILLIN PLUS TAZOBACTAM; VABORBACTAM; ANTIINFECTIVE AGENT; BORONIC ACID DERIVATIVE;

CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; DRUG ACTIVITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EPITHELIAL LINING FLUID; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MIC50; MIC90; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; PYELONEPHRITIS; REVIEW; URINARY TRACT INFECTION; ANIMAL; BACTERIAL INFECTION; CHEMISTRY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BORONIC ACIDS; HUMANS; MEROPENEM;

EID: 85046034630     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028018763288     Document Type: Review

References (49)

1. World Health Organization. Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis. Geneva, Switzerland: WHO; 2017. http://www.who.int/medicines/areas/rational_use/antibacterial_agents_clinical_development/en/. Accessed November 8, 2017
2. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother. 2010;54:969–976. doi:10.1128/AAC.01009-09
3. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl 1):S28–S36. doi:10.1093/infdis/jiw282
4. Tumbarello M, Viale P, Viscoli C. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–950. doi:10.1093/cid/cis588
5. Felty AR, Keefer CS. Bacillus coli sepsis. JAMA. 1924;82:1430–1433
6. Wright H, Bonomo RA, Paterson DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017;23:704–712. doi:10.1016/j.cmi.2017.09.001
7. Avycaz® (ceftazidime/avibactam) [prescribing information]. Irvine, CA: Allergan USA, Inc; 2017
8. Shields RK, Nguyen MH, Chen L. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61:e00883–17. doi:10.1128/AAC.00883-17
9. Shields RK, Potoski BA, Haidar G. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63:1615–1618
10. King M, Heil E, Kuriakose S. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61:e00449–17. doi:10.1128/AAC.00449-17
11. Caston JJ, Lacort-Peralta I, Martin-Davila P. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.021
12. Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase producing K pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4:ofx101. doi:10.1093/ofid/ofx101
13. Both A, Buttner H, Huang J. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate. J Antimicrob Chemother. 2017;72:2483–2488. doi:10.1093/jac/dkx179
14. Vabomere® (meropenem/vaborbactam) [prescribing information]. Parsippany, NJ: The Medicines Company; 2017
15. Zhanel GG, Wiebe R, Dilay L. Comparative review of the carbapenems. Drugs. 2007;67:1027–1052
16. Merrem® (meropenem) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals, LP; 2016
17. Lomovskaya O, Sun D, Rubio-Aparicio D. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e01443–17. doi:10.1128/AAC.01443-17
18. Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61:e00567–17. doi:10.1128/AAC.00567-17
19. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Test. 27th ed. Wayne, PA: CLSI; 2017. CLSI supplement M100
20. Castanheira M, Huband MD, Flamm RK, Jones RN. Meropenem-vaborbactam (MER-VAB) tested against contemporary Enterobacteriaceae isolates from USA hospitals [poster 452]. Poster presented at: ASM Microbe 2016; June 16-20, 2016; Boston, MA
21. Castanheira M, Mendes RE, Flamm RK. Activity of meropenem/RPX7009 and comparator agents tested against contemporary Enterobacteriaceae isolates collected from bloodstream infections in USA hospitals [poster C-152]. Poster presented at: ICAAC/ICC 2015; September 17-21, 2015; San Diego, CA
22. Lapuebla A, Abdallah M, Olafisoye O. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59:4856–4860. doi:10.1128/AAC.00843-15
23. Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62:pii: e01904–17. doi:10.1128/AAC.01904-17
24. Munson E, Huband MD, Castanheira M, Fedler KA, Flamm RK. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination. Diagn Microbiol Infect Dis 2018;90:324–328. doi:10.1016/j.diagmicrobio.2017.11.019
25. Griffith DC, Loutit JS, Morgan EE, Durso S, Dudley MN. Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother. 2016;60:6326–6332. doi:10.1128/AAC.00568-16
26. Wenzler E, Gotfried MH, Loutit JS. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother. 2015;59:7232–7239. doi:10.1128/AAC.01713-15
27. Nicolau DP. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis. 2008;47(suppl 1):S32–S40. doi:10.1086/590064
28. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116–1123
29. Lee LS, Kinzig-Schippers M, Nafziger AN. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis. 2010;68:251–258. doi:10.1016/j.diagmicrobio.2010.06.012
30. Bhavnani S, Dudley M, Landersdorfer C. CLSI carbapenem susceptibility breakpoint changes [poster A1382]. Poster presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2010; Boston, MA
31. Sabet M, Tarazi Z, Nolan T. Activity of meropenem/vaborbactam in mouse models of infection due to KPC-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2017;62:pii: e01446–17. doi:10.1128/AAC.01446-17
32. Sabet M, Tarazi Z, Rubio-Aparicio D. Activity of simulated human dosage regimens of meropenem and vaborbactam against carbapenem-resistant Enterobacteriaceae in an in vitro hollow fiber model [published online November 13, 2017]. Antimicrob Agents Chemother. doi:10.1128/AAC.01969-17
33. Rempex Pharmaceuticals. Efficacy, safety, tolerability of meropenem-vaborbactam compared to piperacillin/tazobactam in complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP), in adults. https://clinicaltrials.gov/ct2/show/NCT02166476?term=NCT02166476&rank=1. Accessed September 10, 2017
34. The Medicines Company. The Medicines Company announces positive top-line results for phase 3 TANGO 1 clinical trial of Carbavance. http://www.themedicinescompany.com/investors/news/medicines-company-announces-positive-top-line-results-phase-3-tango-1-clinical-trial. Accessed September 10, 2017
35. Walsh TJ, Bhowmick T, Darouiche RO. Meropenem-vaborbactam (Vabomere) vs. piperacillin-tazobactam in TANGO I (a phase 3, randomized, double-blind trial): outcomes by baseline MIC in adults with cUTI or AP. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
36. FDA News Release. FDA approves new antibacterial drug. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm573955.htm. Accessed September 16, 2017
37. Rempex Pharmaceuticals. Efficacy, safety, tolerability of Carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults (NCT02168946). https://clinicaltrials.gov/ct2/show/study/NCT02168946?term=vaborbactam&rank=4&view=results. Accessed September 10, 2017
38. Kaye KS, Vazquez J, Mathers A. Meropenem-vaborbactam (Vabomere) vs. best available therapy for CRE infections: TANGO II randomized, controlled phase 3 study results. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
39. The Medicines Company. The Medicines Company announces TANGO-2 trial of meropenem-vaborbactam (formerly, Carbavance) stopped early for superior benefit-risk compared to best available therapy for CRE. http://www.themedicinescompany.com/investors/news/medicines-company-announces-tango-2-trial-meropenem-vaborbactam-formerly-carbavance. Accessed September 10, 2017
40. Wunderink R, Giamarellos-Bourboulis EJ, Rahav G. Meropenem-vaborbactam (Vabomere) vs. best available therapy for carbapenem-resistant Enterobacteriaceae infections in TANGO II: primary outcomes by site of infection. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
41. Lomovskaya O, Castanheira M, Vazquez J. Assessment of MIC increases with meropenem-vaborbactam (Vabomere) and ceftazidime-avibactam in TANGO II a phase 3 study of the treatment of CRE infections. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
42. Paterson D, Kwak EJ, Bhowmick T. Meropenem-vaborbactam (Vabomere) vs. best available therapy for carbapenem-resistant Enterobactericeae in TANGO II: outcomes in immunocompromised patients. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
43. Mathers A, Hope W, Kaye KS. Meropenem-vaborbactam (Vabomere): outcomes in subjects with renal impairment in phase 3 studies TANGO I and II. Poster presented at: ID Week 2017; October 7, 2017; San Diego, CA
44. The Medicines Company. A study of meropenem-vaborbactam versus piperacillin/tazobactam in participants with hospital-acquired and ventilator-associated bacterial pneumonia (TANGOIII). https://clinicaltrials.gov/ct2/show/study/NCT03006679?term=vaborbactam&rank=2. Accessed September 10, 2017
45. Rempex Pharmaceuticals. Dose-finding, pharmacokinetics, safety, and tolerability of meropenem-vaborbactam in pediatric subjects with serious bacterial infections. https://clinicaltrials.gov/ct2/show/record/NCT02687906?term=vaborbactam&rank=1. Accessed September 16, 2017
46. Spriet I, Goyens J, Meersseman W, Wilmer A, Willems L, Van Paesschen W. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007;41:1130–1136
47. Kidd JM, Avery LM, Asempa TE, Nicolau DP, Kuti JL. Physical compatibility of meropenem and vaborbactam with select intravenous drugs during simulated Y-site administration. Clin Ther. 2018;40:261–269. doi:10.1016/j.clinthera.2017.12.007
48. Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States medical centers (2013-2016). Antimicrob Agents Chemother. 2017;61:e01045–17. doi:10.1128/AAC.01045-17
49. Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60:5454–5458. doi:10.1128/AAC.00711-16